Iron infusion better than iron pill for treating anaemia after GI bleeding
Administering ferric carboxymaltose (FCM) infusion results in faster and more efficient normalization of haemoglobin (Hb) and iron status parameters, with a better tolerability profile, when compared with oral ferrous sulphate (FeSulf) in patients with anaemia secondary to acute gastrointestinal (GI) bleeding, as shown in a recent study.
The 42-day study randomized 61 adult patients with Hb <10 g/dL upon discharge (day 0) to receive FCM (n=29; 1,000 mg on day 0; 500 or 1,000 mg on day 7; per label) or FeSulf (n=32; 325 mg/12 hours for 6 weeks).
Complete response rate (Hb ≥12 g/dL in women and ≥13 g/dL in men) at day 42, the primary outcome measure, was higher in the FCM than in the FeSulf group (100 percent vs 61.3 percent; p<0.001). Of note, this difference was observed as early as day 21 (85.7 percent vs 45.2 percent; p=0.001).
Results for secondary outcomes were also more favourable with FCM. Significantly more FCM- vs FeSulf-treated patients achieved partial response (Hb increment ≥2 g/dL from baseline) at days 21 (100 percent vs 67.7 percent; p=0.001) and 42 (100 percent vs 74.2 percent; p=0.003), as well as normalization of transferrin saturation to ≥25 percent by the end of the study period (76.9 vs 24.1 percent; p<0.001).
None of the patients in the FCM group reported any adverse event in comparison with 10 patients in the FeSulf group (eg, constipation and abdominal pain).
According to researchers, the present data could provide clinical support for the inclusion of ferric carboxymaltose into treatment schemes and guidelines in the management of patients with anaemia following acute haemorrhage of GI origin.